Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean
This study was terminated on 03Feb2011 due to the fact that the anticipated number of
patients expected was not reached. The date of cessation of the drug was January 27, 2011.
There was no intervention in the treatment or administration of the drug; the study only
observed the treatment and collected data. As the study was dependent on the arrival of new
patients with metastatic renal cancer, which was of a very low incidence, the study was
terminated. Efficacy, adverse events or other safety issues were not factors in terminating
the study. Lack of patients was the only reason.
Observational Model: Cohort, Time Perspective: Prospective
Rate of patients that present metastasis when consulting for first time
Pfizer CT.gov Call Center
Costa Rica: Centro de Desarrollo Estratégico e Información en Salud y Seguridad Social (CENDEISSS)